This 4+ Year Old Website Has 1,000+ High Quality Articles
Written By Qualified Experts After Thorough Research.
As An Authority INFORMATIONAL Website, It Is Updated DAILY.
You Should Always Revisit For Latest On Prostate Cancer!

The Prostate Cancer Market Is Increasing As Result Of Life Extending Innovative Drugs – Research

The prospect of growth for the prostate cancer market is looking brighter. It has been estimated that by 2015, the market may grow to a value of about $7.8 billion.

This is a significant increase and a worthy projection due to increase innovative drugs that helps in improving the survival rates of patients suffering from the disease.

Many notable medications have been developed and are making the future growth of the market look brighter. More significantly is the introduction of drugs from Dendreon and Medivation.

Here are more interesting details on the future outlook for prostate cancer medication sales:

Prostate cancer is the third most common type of cancer in men with approximately 500,000 cases diagnosed annually [1]. About half of these cases occur in the United States and about 2 million American men are living with the disease [2]. It is estimated that the prostate cancer market may grow to $7.8 billion by 2015 [3]. An aging population and the introduction of new, innovative drugs, which extend survival rates in patients with advanced prostate cancer, are significant factors fueling market growth.

The majority of new prostate cancer treatments are focused on extending long-term survival. In early stage prostate cancer, hormone therapy, which slows testosterone induced tumor growth, is the first-line treatment intended to minimize prostate tumor growth and prevent bone metastases. Zoladex (goserelin), a gonadotropin releasing hormone agonist, is an example of a treatment that is used before and during radiation therapy in patients with localized prostate cancer.

A combination treatment of Zoladex, flutamide, and radiation treatment has shown a significant increase in median disease-free survival of 4.4 years compared to 2.6 years for radiation alone (p<0.001)[4]. Zoladex, with $1.1 billion in annual sales, is sold by AstraZeneca (AZN) to treat prostate cancer and breast cancer. While many patients’ prostate cancer is held at bay by hormone therapy, resistance and progression frequently occur in these patients. Patients who have progressed despite hormone therapy and whose disease has spread outside the prostate are said to have metastatic, castration-resistant prostate cancer (mCRPC).

Sanofi’s (SNY) Taxotere (docetaxel), an anti-mitotic chemotherapy, has been the first treatment choice for mCRPC patients. Before hitting the patent cliff in 2010, Taxotere accounted for 23% of the total sales of prostate cancer drugs. It was the first chemotherapy shown to extend survival rates of hormone refractory prostate cancer patients, with median overall survival of 18.9 months compared to 16.5 months for mitoxantrone (p<0.001) in a randomized, controlled trial. Taxotere chemotherapy is associated with severe side effects including neutropenia, leukopenia, anemia, hair loss, fluid retention, mouth sores, weakness, and in some patients, nerve pain.

Before losing patent protection, Taxotere sales peaked near $2 billion annually but dipped to $1 billion in 2011 and continue to slide. In order to shore up this franchise, Sanofi has received initial approval for and continues to develop the antimitotic drug Jevtana (cabazitaxel). Click here to read the full extract.

From the full extract above, it becomes clear that the market for prostate cancer is going to increase in the next couple of years.

Innovative medications have shown to help in improving the lives of individuals.

At least, if not for anything, many patients will prefer to get treated medications that can improve or extend their lives.

Most of the new treatments used against metastatic, castration resistance prostate cancer (mCRPC) have shown these potencies. Provenge from Denderon and Enzalutamide from Medivation are notable examples.

Below Are Other Related Articles Among 1,000+Prostate Cancer Articles On This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:(95% of these 1,000+ Prostate Cancer Articles on this website are written by our Expert In -house Writers, after lots of research. The remaining 5% are news articles and videos from relevant sources!)